| BACKGROUND
Levobupivacaine is the S (−) enantiomer of racemic bupivacaine, displaying a lower risk of cardiovascular and central nervous system toxicity while still retaining local anesthetic potency. 1 In pediatric patients, the elimination increases with age and reaches 80% of the adult capacity by the age of 6 months. 2 Present protocols of caudalepidural infusions of levobupivacaine are based upon studies of bupivacaine and pharmacokinetic modeling. [3] [4] [5] Previous studies of levobupivacaine are limited to examining serum concentrations of levobupivacaine in infants following a single caudal-epidural bolus dose. [6] [7] [8] A bolus dose followed by an infusion for 24 hours has been studied in infants over 6 months. 9 At the same time, studies of racemic bupivacaine in infants 10 and neonates, 11 with infusion periods of 12 and 48 hours, respectively, have raised concerns over its safety in this age group. 4 A study of serum concentrations of levobupivacaine after a loading dose followed by an infusion for 48 hours, in infants aged 3-6 months, would help inform clinical practice. By restricting the age group, we focus on the maturation of the liver and clearance with age in these infants. Since the unbound local anesthetic is responsible for toxicity, the degree of binding to the acute phase protein, α 1 -acid glycoprotein (AAG), should be considered.
Bladder exstrophy is a rare congenital abnormality, with an incidence of 1:45 500, 12 Here we present a clinical trial examining serum concentrations of total levobupivacaine and AAG in this group of patients.
| Aims
To use pharmacokinetic analysis to predict the unbound levobupivacaine concentrations for the study protocol.
To use pharmacokinetic modeling and consider the safety of alternative dosing schedules, such as increasing the loading dose and an earlier onset of the maintenance infusion.
| MATERIALS AND METHODS
This study was conducted as a Phase II/III clinical trial (EudraCT no:
2015-000393-34) with the MHRA (21387/0235/001-0001) and
Northwest Ethics Committee approval (15/NW/0240). The trial was conducted in compliance with the protocol, following GCP guidelines. Written informed consent was obtained from parents.
The study population consisted of infants aged 3-6 months undergoing repair of bladder exstrophy.
The exclusion criteria were lack of consent, hypersensitivity to local anesthetics, history of seizures or neurological disorders, bradyarrhythmias, blood clotting disorders, and congenital abnormalities precluding regional anesthesia.
The trial was designed in several stages. A literature-based joint LBU and AAG pharmacokinetic model was developed to predict the impact of changes of AAG concentrations, associated with surgery, on total levobupivacaine concentrations. Prospective pharmacokinetic simulations of levobupivacaine and AAG were carried out in Matlab R2012a (Mathworks, Natick, MA) to inform the blood sampling strategy. This was based on a population pharmacokinetic model of unbound levobupivacaine following a caudal injection of levobupivacaine 2 mg/kg given over 30 seconds, in infants undergoing sub-umbilical surgery. 8 The model was modified to account for time-dependent changes in levels of AAG following surgery. 13 It allowed the estimation of optimal sampling time points, limiting blood sample volumes in accordance with the WHO guidance.
14 Optimal design evaluations were performed using PopDes (The University of Manchester; Matlab: http://research.bmh.mancheste r.ac.uk/capkr/softwaretools/) based on the preliminary model. 15 Infants were recruited over a period of 24 months (June 2015-June 2017). The clinical data collected were then used to develop a
What is already known
Levobupivacaine is highly bound to α 1 -acid glycoprotein, an acute phase protein, where unbound levobupivacaine is responsible for toxicity.
While the pharmacokinetics of racemic bupivacaine has been studied for infusions up to 48 hours in neonates and up to 4 hours in infants, the pharmacokinetics for levobupivacaine has only been studied after a single shot caudal administration.
What this article adds
In infants aged 3-6 months, using current recommended This was tunneled to the right flank and the catheter tip position was confirmed using fluoroscopy.
| Caudal-epidural dosing regime
A loading dose of levobupivacaine 0.25% 2 mg/kg (0.8 mL/kg) was injected over 5 minutes (start of loading dose was time zero). A maintenance infusion of levobupivacaine 0.125% 0.2 mg/kg/h with clonidine (1.5 mcg/mL) 16 was started 1 hour after time zero and run for 47 hours. 4, 11 All infants also received a remifentanil infusion (25 mcg/mL) intraoperatively which was titrated as required. The caudal-epidural infusion was stopped after 47 hours and blood samples were collected for analysis up to 72 hours after the loading dose.
| Blood sampling
Blood samples were taken from the indwelling central venous catheter. Dead space sampling was performed and the volume from the dead space was injected back using antiseptic non-touch technique.
No intravenous fluids were administered through the central line.
The samples were collected in plain glass pyrex tubes for levobupivacaine (2 mL/sample) and lithium heparin for AAG (0.8 mL/sample).
The samples were labeled 1 to 9 with sampling time points at 0.25,1, 2, 4, 12, 36, 48, 60, and 72 hours. (Table S1 ).
| Blood sample management
All samples were anonymized for analysis, identifiable only by a unique number to allow data linkage. Blood samples were stored at 4°C then centrifuged in the laboratory. The serum was then stored at −80°C. 
Analysis of levobupivacaine was undertaken in

| Statistical analysis
This study was conducted as a Phase II/III clinical trial. It was designed as an exploratory observational study to develop the pharmacokinetic model in this age group with an aim to be used to inform further studies. It aimed to recruit 10 infants over a 2-year period, with a final sample of eight infants. All parents approached, consented to participate in the trial. Descriptive statistics and graphs were used to explore the serum concentration-time profiles and the between patient variability. Rv3.0.2 software (https://www.r-project.
org/) was used for this descriptive and graphical analysis. 
| Data management
All data were anonymized and only identifiable by a unique study number allocated at recruitment. Data collection was performed by one of the investigators and stored in both paper and electronic form.
| Pharmacokinetic analysis
Population pharmacokinetic modeling was carried out to analyze the generated clinical data (total levobupivacaine and AAG) from eight infants. This was performed using NONMEM 7.3 (ICON plc, Dublin, Ireland). Identifiability analysis of the proposed AAG and levobupivacaine models was carried out using the software DAISY (Differential Algebra for Identifiability of Systems; University of Cagliari, Cagliari, Italy) 20 and the models were found to be globally identifiable. Due to the limited dataset (n patients = 8), covariate analysis was not considered. Data below the LLOQ were included in the analysis (7
out of a total 66 data points were used in analysis, or 10.6%) as per the all data approach recommended by Keizer et al. 21, 22 In one of the infants (infant 3), the levobupivacaine infusion was (Figure 3) . This showed consistency with the predicted plasma concentration-time profiles that were simulated prospectively to inform the study design ( Figure S2 , Data S1). The final AAG model was modified from a Hill function to an empirical precursor model with an interaction term to best describe the observed data in this study ( Figure 1 ; Equations S2 and S3 Data S1, and Table 1 (Table 1) . Figures 2 and 3 show the visual predictive checks (number of simulations = 10 000) for total levobupivacaine and AAG over time, respectively.
Pharmacokinetic modeling suggested that unbound levobupivacaine levels quickly reached steady-state concentrations after the short infusion, loading dose of levobupivacaine 0.25% (2 mg/kg). The simulated unbound levels were then maintained throughout the infusion period at around 0.03 mg/L (Figure 4 ). We also simulated an alternative dosing protocol which is the same as that used in infants over 6 months (2.5 mg/kg loading dose) followed immediately by a maintenance infusion of 0.2 mg/kg/h). BSV, interindividual variability presented as %CV (coefficient of variation); CL u /F, apparent unbound clearance; CL 0 , conversion clearance; C (0), concentration of AAG and pre-AAG at time zero; Err prop, proportional residual variability; INT, interaction term; k a , first-order absorption rate; V u /F, apparent unbound volume of distribution; 95% CI are the 95% confidence intervals.
F I G U R E 4
Simulated total (A) and unbound (B) concentrationtime profiles of levobupivacaine (C tot,LBU and C u,LBU , respectively) at the current dosing schedule. C: simulated α 1 -acid glycoprotein concentration (C AAG ) over 72 hours. Median, 95th and 5th percentiles of model simulations indicated by (-) gray area
We chose to conduct this study in infants with bladder exstrophy who require major corrective surgery for the abnormality at an early age. Central venous access is routinely used for monitoring and was used to obtain blood samples. A caudal-epidural catheter is also recommended for pain relief. 24 These patients may potentially benefit from higher doses of local anesthetic, particularly at the time of the osteotomy. However, clinicians are limited by existing dosing protocols due to the possibility of central nervous system and cardiovascular side effects, with higher doses and longer duration of the infusion in infants. Choosing our particular group of infants with a rare congenital abnormality (5-7 infants at our centre per year) limited recruitment to only eight infants.
The small number of study participants prohibited any investigation of covariate associations with pharmacokinetic parameters and resulted in a potential exaggeration of variability in the simulated AAG and levobupivacaine concentration levels. This is not uncommon when analyzing datasets consisting of a small number of study participants.
Levobupivacaine is extensively metabolized by cytochrome P450
(CYP) 3A4 and 1A2. 1,2 Chalkiadis et al 2 found bodyweight, normalized clearance of levobupivacaine to increase following birth and approach 80% of adult values at 6 months of age.
Our results showed that the serum concentration of total levobupivacaine increased after the initial loading dose and continued to rise throughout the infusion period. When the infusion was stopped the levels fell rapidly (Figure 2 ). This confirms findings by
Larsson et al 11 with bupivacaine in neonates receiving epidural infusions.
Concentrations of AAG were shown to increase during the course of the surgery and appeared to plateau toward the end of the study period, which is consistent with previous studies. 23 The magnitude of increase in AAG observed in this study is larger (approximately a fourfold median increase) compared to that observed by Booker et al 25 (approximate twofold increase) and in the model developed by Aarons et al. 13 As a result of rich sampling at early time points, we observed a minor but consistent reduction in AAG concentrations in the immediate hours after the levobupivacaine, loading dose. This can be best described using an empirical precursor model, inhibiting AAG formation and simultaneously inducing precursor formation. This provides a reasonable description of the observed data. Care should be taken not to make inferences about the underlying mechanism based on this model.
Levobupivacaine displays linear binding to AAG, binding around 97%. 1 Concentration-dependent plasma protein binding with low to moderate hepatic extraction drugs such as levobupivacaine, will cause variation in total drug concentrations and associated pharmacokinetic parameters, whereas unbound concentrations and parameters will remain unaffected. 8 Ideally, the unbound drug concentration should be measured as it drives pharmacological and toxicological effect. The inability to measure these data is an apparent limitation of the current study. However, a study protocol was devised to allow indirect inference of unbound levobupivacaine concentrations and unbound pharmacokinetic parameters by incorporating information on total levobupivacaine and AAG concentrations, and K D , based on published adult data. 23 The developed model was successful in describing the time-dependent change in total levobupivacaine concentrations due to changes in AAG and gave an indication of the unbound levobupivacaine concentration-time profile. Estimated CLu/F was higher and Vu/F was lower compared to that reported by Chalkiadis et al. 8 This may be due several factors, including age differences of study participants in the two clinical trials (ontogeny of clearance) 2 and differences in study duration (4 hours vs 72 hours here). Further, the approach detailed here is susceptible to uncertainty in the determination of K D and its ontogeny. 23 Aarons et al 13 receiving a caudal-epidural, which is sometimes, required with the present local anesthetic dosage limitations. However, further studies are needed to confirm this. Evidence suggests keeping serum total bupivacaine levels below 2-2.5 mg/L to avoid toxicity. 4 Levobupivacaine has an improved safety profile 1,6-8 but there are no studies indicating unbound serum levobupivacaine toxic levels.
Some of the individual profiles indicated complex absorption kinetics from the epidural space. This would perhaps be best described using a combined slow and fast absorption rate as previously shown through modeling of epidural levobupivacaine in adults. 26 The complex absorption was however only apparent in a small proportion of study participants and not significant enough to allow inclusion in the current model.
All infants required blood transfusion. The effect of blood transfusion is rarely considered in pharmacokinetic analysis and little is known about its impact on drug disposition. Although theoretically possible, no apparent trends were seen when comparing blood transfusion volumes to estimated individual pharmacokinetic parameters.
Clonidine is a common adjuvant to levobupivacaine in a single dose or caudal infusions. Clonidine was a non-investigational medicinal product (NIMP) in this clinical trial and was used in a concentration of 1.5 mcg/mL based on previous studies. 16, 27 Chalkiadis et al 16 indicated that levobupivacaine is more rapidly absorbed from the caudal-epidural space when clonidine is added. While we were not able to compare levobupivacaine absorption pharmacokinetics with and without clonidine, total serum concentrations of levobupivacaine were well below suggested toxic levels throughout the study.
One of the infants (infant 3) had to be excluded from data analysis as this infant was reintubated and caudal catheter was removed at 12 hours due to high-grade pyrexia and respiratory distress. This was recorded as a serious adverse event (SAE). Viral and bacterial titers were negative and the infant was extubated after 48 hours.
Pain scores remained below four (FLACC) in all infants using prescribed rescue analgesia.
| CONCLUSION
This trial has allowed the development of a pharmacokinetic model for the studied age group combining levobupivacaine and AAG data.
The simulated concentration-time profiles show that unbound levobupivacaine concentrations reach an early steady-state level following the loading dose and the simulated steady-state concentrations are below suggested toxic concentrations. Hence, it is possible to increase the duration of the infusion to more than 48 hours.
The current dosing recommendations may be too conservative when using levobupivacaine in the studied age group. However, over a broader age range, variation in elimination or a compromised liver function must be taken into consideration.
